Welcome to our dedicated page for Insulet news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet stock.
Insulet Corporation (PODD) delivers innovative diabetes management solutions through its flagship Omnipod® insulin pump system. This page aggregates official news and developments about the company's medical device innovations, financial performance, and strategic initiatives.
Investors and healthcare professionals will find timely updates including quarterly earnings reports, product launch announcements, regulatory milestones, and partnership agreements. All content is sourced directly from verified corporate communications to ensure accuracy.
Key coverage areas include FDA clearances for new devices, clinical study results, international market entries, and technology partnerships enhancing insulin delivery systems. The resource is particularly valuable for tracking advancements in tubeless pump technology and automated insulin dosing integrations.
Bookmark this page for streamlined access to Insulet's latest developments in diabetes care innovation. Check regularly for updates that may impact long-term growth strategies or patient care standards.
Insulet (NASDAQ: PODD), a leader in tubeless insulin pump technology, has announced plans to offer $450 million in senior unsecured notes due 2033 through a private placement. The company intends to use the proceeds, along with cash on hand, to manage its existing 0.375% Convertible Senior Notes due 2026.
Additionally, Insulet plans to amend its Credit Agreement to extend its revolving credit facility maturity from 2028 to 2030 and increase revolving credit commitments by up to $200 million, potentially reaching aggregate commitments of up to $500 million. Both transactions are subject to market conditions and may not proceed as described.
The Notes will be exclusively offered to qualified institutional buyers under Rule 144A and non-U.S. persons outside the United States under Regulation S of the Securities Act of 1933.
Insulet (NASDAQ: PODD) has announced the expansion of its Omnipod 5 Automated Insulin Delivery System to four new international markets. The system is now commercially available in Australia with Dexcom G6 and G7 compatibility, and will soon launch in Belgium, Canada, and Switzerland.
The tubeless insulin delivery system features SmartAdjust™ technology that automatically adjusts insulin delivery every five minutes. In Australia, plans are underway to add Abbott's FreeStyle Libre® 2 Plus compatibility. Belgium will have access to both Abbott's FreeStyle Libre 2 Plus and Dexcom G6/G7 integrations. Canada and Switzerland launches are scheduled for spring, with varying sensor compatibilities.
Additionally, Insulet plans to expand to five more markets including Israel, Saudi Arabia, UAE, Qatar, and Kuwait, with timing to be announced. The company recently added Dexcom G7 integration for Omnipod 5 users in the UK and Netherlands.
Insulet (NASDAQ: PODD) will present results from its multinational RADIANT trial at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in March 2025. The study compared the Omnipod 5 Automated Insulin Delivery System to multiple daily injections in type 1 diabetes patients aged 4-70 years across France, UK, and Belgium.
The RADIANT trial marks two significant firsts: it's the first randomized controlled trial examining direct transition from multiple daily injections to an automated insulin delivery system, and the first to assess an AID system with Abbott FreeStyle Libre 2 sensors. Results will be presented at a symposium featuring renowned medical experts, including Dr. Emma Wilmot, Dr. Chantal Mathieu, and Dr. Brynn Marks.
The conference will showcase 11 presentations and posters on Omnipod 5 and Omnipod DASH systems, covering various aspects including real-world outcomes, comparative studies, and specific use cases in both Type 1 and Type 2 diabetes patients.
Insulet (NASDAQ: PODD), the global leader in tubeless insulin pump technology, has announced its upcoming Investor Day scheduled for June 5, 2025 at their global headquarters in Acton, Massachusetts.
The event, running from 10:00 a.m. to 1:30 p.m. (ET), will feature presentations by President and CEO Jim Hollingshead, Executive Leadership Team members, and independent experts. The agenda will cover:
- Comprehensive overview of the Omnipod® 5 platform
- Strategic priorities and market opportunities
- Growth drivers and innovation roadmap
- Financial outlook
While in-person attendance is by invitation only, investors can join via live webcast through the company's Investor Relations website. The webcast replay and presentations will be available post-event at investors.insulet.com under 'Events and Presentations'.
Insulet (NASDAQ: PODD) reported strong financial results for 2024, with full-year revenue reaching $2.1 billion, up 22.1% year-over-year. This marks the company's 9th consecutive year of 20%+ constant currency revenue growth.
Key highlights include:
- Total Omnipod revenue grew 22.4% to $2.0 billion
- U.S. Omnipod revenue increased 20.6% to $1.5 billion
- International Omnipod revenue rose 27.6% to $523.4 million
- Gross margin improved to 69.8%, up 150 basis points
- Net income reached $418.3 million, or $5.78 per diluted share
The company achieved significant milestones, including reaching 500,000 estimated active global customers using Omnipod products, with 365,000 using Omnipod 5. For 2025, Insulet projects revenue growth of 16-20% with gross margin of approximately 70.5% and operating margin of approximately 16.5%.
Insulet (NASDAQ: PODD) has expanded the availability of its Omnipod 5 Automated Insulin Delivery System to five additional European countries: Italy, Denmark, Finland, Norway, and Sweden. The system is now compatible with both Abbott's FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring sensors, making it the first and only tubeless automated insulin delivery system integrated with both leading CGM sensor brands.
The Omnipod 5 system, indicated for individuals aged two years and older with type 1 diabetes, is currently the number one insulin pump for new users in Europe and the most prescribed AID system in the U.S. The system is waterproof and features proactive glucose control. Clinical results and real-world evidence have shown improvements in A1c levels and time in range while maintaining low hypoglycemia rates.
Insulet (NASDAQ: PODD), the global leader in tubeless insulin pump technology, has scheduled the release of its fourth quarter and full year 2024 financial results for February 20, 2025, after market close. Management will host a conference call at 4:30 p.m. Eastern Time on the same day.
The company's primary product, the Omnipod Insulin Management System, offers a tubeless disposable Pod providing up to three days of continuous insulin delivery. Their flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with continuous glucose monitoring and can be controlled via smartphone in the U.S. or through the Omnipod 5 Controller, eliminating the need for multiple daily injections and fingersticks.
Insulet (NASDAQ: PODD) has won a significant legal victory against EOFlow Co., in the U.S. District Court for the District of Massachusetts. The jury found that EOFlow and other defendants misappropriated Insulet's trade secrets, awarding $452 million in total damages. This includes $170 million in compensatory damages and $282 million in exemplary damages for willful and malicious misappropriation. The verdict came after a four-week trial, though EOFlow's ability to pay the damages remains uncertain.
Insulet (NASDAQ: PODD) announced that its Omnipod 5 Automated Insulin Delivery System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring sensor in the U.S. This integration makes Omnipod 5 the most connected tubeless AID system in the U.S. and the only AID system indicated for both type 1 and type 2 diabetes. The Omnipod 5 System automatically adjusts insulin delivery every five minutes using SmartAdjust technology, eliminating the need for multiple daily injections while improving diabetes management outcomes.
Insulet (NASDAQ: PODD), the leader in tubeless insulin pump technology, announced its participation in three upcoming investor conferences: The 6th Annual Wolfe Research Healthcare Conference in New York (November 20, 2024), The Nasdaq 51st Investor Conference in London (December 10, 2024), and The J.P. Morgan 43rd Annual Healthcare Conference in San Francisco (January 14, 2025).
The company's flagship product, the Omnipod 5 Automated Insulin Delivery System, offers a unique tubeless insulin delivery solution that integrates with continuous glucose monitoring, requiring no daily injections or fingersticks, and can be controlled via smartphone in the U.S. Live audio webcasts of the presentations will be available on the company's investor relations website.
FAQ
What is the current stock price of Insulet (PODD)?
What is the market cap of Insulet (PODD)?
